Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
The add-on effect of Chinese herbal medicine on COVID-19: A systematic review and meta-analysis

Xufei Luo \textsuperscript{a,1}, Xiaojia Ni \textsuperscript{b,1}, Jialiu Lin \textsuperscript{b,1}, Yidan Zhang \textsuperscript{b,1}, Lei Wu \textsuperscript{b}, Donghui Huang \textsuperscript{b,1}, Yuntao Liu \textsuperscript{b,1}, Jianwen Guo \textsuperscript{b}, Wanxin Wen \textsuperscript{b}, Yefeng Cai \textsuperscript{a,1,***}, Yaolong Chen \textsuperscript{a,d,e,f,g,***}, and Lin Lin \textsuperscript{b,1,***}

\textsuperscript{a} School of Public Health, Lanzhou University, Lanzhou, China
\textsuperscript{b} Guangdong Provincial Hospital of Chinese Medicine, Guangdong Provincial Academy of Chinese Medical Sciences, The Second Clinical School of Guangzhou University of Chinese Medicine, Guangzhou, China
\textsuperscript{c} Guangdong Provincial Key Laboratory of Research on Emergency in TCM, Guangzhou, China
\textsuperscript{d} Evidence-based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China
\textsuperscript{e} Lanzhou University, an Affiliate of the Cochrane China Network, Lanzhou China
\textsuperscript{f} Key Laboratory of Evidence Based Medicine and Knowledge Translation of Gansu Province, Lanzhou University, Lanzhou, China

\textbf{Abstract}

\textbf{Background:} Chinese herbal medicine (CHM) is thought to be a potential intervention in the treatment of coronavirus disease (COVID-19).

\textbf{Purpose:} This study aimed to investigate the efficacy and safety of CHM or CHM combination therapy for COVID-19.

\textbf{Study design:} Systematic review and meta-analysis

\textbf{Methods:} We searched for relevant studies in the CNKI, CBM, Wanfang Data, PubMed, Cochrane Library, Embase, and other resources from their inception to April 15, 2020. Randomized controlled trials, cohort studies, and case-control studies on CHM or CHM combination therapy for COVID-19 were included. Meta-analysis was performed according to the Cochrane Handbook.

\textbf{Results:} Overall, 19 studies with 1474 patients were included. Meta-analysis showed that the overall clinical effectiveness (OR = 2.67, 95% CI 1.83-3.89, \(I^2 = 0\%\)), improvement in the CT scan (OR = 2.43, 95% CI 1.80-3.29, \(I^2 = 0\%\)), percentage of cases turning to severe/critical (OR = 0.40, 95% CI 0.24-0.67, \(I^2 = 17.1\%\)), reverse transcription-polymerase chain reaction (RT-PCR) negativity rate (OR = 2.55, 95% CI 1.06-6.17, \(I^2 = 56.4\%\)) and disappearance rate of symptoms (fever, cough, and fatigue) were superior by combined CHM treatment of COVID-19. However, there was no statistical difference between the two groups in terms of length of hospital stay (WMD = 0.46, 95% CI -3.87 - 2.95, \(I^2 = 99.5\%\)), and rate of adverse effects (OR = 1.21, 95% CI 0.48-3.07, \(I^2 = 43.5\%\)). The quality of evidence was very low to low.

\textbf{Conclusion:} The combined treatment of COVID-19 with Chinese and Western medicine may be effective in controlling symptoms and reducing the rate of disease progression due to low quality evidence.

\textbf{Keywords:} Chinese herbal medicine; COVID-19; systematic review; meta-analysis

\textbf{Abbreviations:} CHM, Chinese herbal medicine; COVID-19, coronavirus disease 2019; RT-PCR, reverse transcription-polymerase chain reaction; WHO, World Health Organization; PHEIC, Public Health Emergency of International Concern; NHC PRC, National Health Commission of the People’s Republic of China; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-analysis; AE, adverse effects; CNKI, China National Knowledge Infrastructure; CBM, China Biology Medicine; RCT, randomized controlled trials; CT, computed tomography; RoB, Risk of Bias; NOS, Newcastle-Ottawa Scale; GRADE, Grading of Recommendations Assessment, Development and Evaluation; OR, odds ratios; CI, confidence intervals; WMD, weighted mean differences.

* Corresponding author: Professor Yefeng Cai, Department of Neurology, Guangdong Provincial Hospital of Chinese Medicine, No. 111, Dade Road, Guangzhou 510120, China.

** Corresponding author: Professor Yaolong Chen, Evidence-based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, China.

*** Corresponding author: Professor Lin Lin, Department of Respiratory Medicine, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou 510120, China.

E-mail addresses: caiyefeng@126.com (Y. Cai), chenyao@tsa.edu.cs (Y. Chen), drlinlin620@163.com (L. Lin).

1 These authors contributed equally to this work.

https://doi.org/10.1016/j.phymed.2020.153282

Received 30 April 2020; Received in revised form 30 June 2020; Accepted 10 July 2020

Available online 11 July 2020

0944-7113/© 2020 Elsevier GmbH. All rights reserved.
Introduction

An unexplained pneumonia has spread rapidly throughout the country since early 2020 (She et al., 2020). The disease is caused by SARS-CoV-2, a novel coronavirus, and presents with manifestations of pneumonia such as cough, fever, fatigue, dyspnea, among others (Fu et al., 2020). On February 11, 2020, the World Health Organization (WHO) named the disease caused by the virus as coronavirus disease (COVID-19) (WHO, 2020a). On January 30, 2020, the WHO declared the outbreak a Public Health Emergency of International Concern (PHEIC) (WHO, 2020b) and as a pandemic on March 11, 2020 (WHO, 2020c). As of April 15, 2020, more than 1,910,000 cases had been diagnosed in 210 countries outside China, with over 123,000 deaths (WHO, 2020d).

Chinese herbal medicine (CHM) was considered important by the health authorities of the country in the fight against COVID-19 (Yang et al., 2020). At the beginning of the COVID-19 outbreak, due to the unknown nature of the disease, there were no effective western medicine treatment protocols and vaccines approved for clinical use. However, in most hospitals in China, traditional Chinese medicine has been used widely and has played an important role in controlling the symptoms of COVID-19, either as monotherapy or in combination with western medicine (Du et al., 2020). Presently, the National Health Commission of the People’s Republic of China (NHC PRC) has issued seven editions of the COVID-19 management protocol (NHC, 2020a), with inclusion of CHM in the third edition, which has been continuously optimized in subsequent editions (NHC, 2020b). Chinese researches have also developed several clinical practice guidelines for COVID-19 (Ho et al., 2020; Ang et al., 2020). Moreover, a number of systematic reviews on the efficacy of CHM for the treatment of COVID-19 have been conducted (Luo et al., 2020; Wu et al., 2020). However, the majority of these reviews have included indirect evidence or incomplete studies, which provide limited clinical guidance. Therefore, we conducted this systematic review to comprehensively investigate and identify the efficacy and safety of CHM treatment in COVID-19.

The purpose of this systematic review and meta-analysis was to investigate the efficacy and safety of CHM or CHM in combination with other interventions for the treatment of COVID-19, to provide clinicians a basis for the use of CHM, and provide information to other countries regarding the experience of treating COVID-19 with CHM in China.

Methods

This study followed the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) statements checklist (Moher et al., 2009) and Cochrane handbook for Systematic Reviews (Higgins et al., 2019). Besides, our systematic review protocol was registered with the International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY) on April 27, 2020 and the registration number is INPLASY2020040190 (Luo et al., 2020a).

Search strategy

We searched for studies in the China National Knowledge
### Table 1
Characteristics of included studies.

| Study            | Study design | Severity of disease | Original place of patients | Complications | Age (Years) | Numbers of T/C (M/F) | Sample size | Intervention | Control | Course of treatment |
|------------------|--------------|---------------------|-----------------------------|---------------|-------------|----------------------|-------------|--------------|----------|---------------------|
| Cheng et al. (2020) | Case-control study | Ordinary | Wuhan | Hypertension, Coronary heart disease, Diabetes, Cerebral infarction | T:55.5 ± 12.3, C:55.8 ± 11.6 | T:51 (26/25), C:51 (27/24) | 102 | Liânhuá Qíngwén granules + Routine treatment | Routine treatment | 7d |
| Qu et al. (2020) | Case-control study | NR | Haozhou | Hypertension, Diabetes | T:38.71 ± 0.71, C:38.62 ± 0.52 | T:40 (25/15), C:30 (16/14) | 70 | Shufeng Jiédu capsule + Arbidol + Moxifloxacin + Routine treatment | Arbidol + Moxifloxacin + Routine treatment | 10d |
| Shi et al. (2020) | Case-control study | Mild (2), Ordinary (54), Severe (11) | Shanghai | Hypertension, Diabetes, Tumor, Fatty liver, Autoimmune liver disease, Complicated with hypertension, diabetes and coronary heart disease, Complicated with hypertension and coronary heart disease | T:47.94 ± 14.46, C:46.72 ± 17.40 | T:49 (26/23), C:18 (10/8) | 67 | Chinese patent medicine or decocition + Routine treatment | Routine treatment | NR |
| Xia et al. (2020) | Case-control study | Ordinary (40), Severe (10), Critical (2) | Hubei | Pulmonary tuberculosis, COPD, Hypertension, Diabetes, Stroke, Chronic nephropathy, Chronic liver disease | T:54.18 ± 13.08, C:53.67 ± 12.70 | T:34 (17/17), C:18 (6/12) | 52 | Chinese patent medicine or decocition or herb injection + Arbidol + Moxifloxacin + Routine treatment | Arbidol + Moxifloxacin + Routine treatment | Decocition:5d; Chinese patent medicine:7d; Herb injection:7-10d |
| Lv et al. (2020) | Case-control study | Suspected case | Wuhan | Hypertension, Coronary heart disease, Diabetes, Cerebral infarction | T:59.1 ± 16.56, C:60.2 ± 17.01 | T:63 (28/35), C:38 (18/20) | 101 | Liânhuá Qíngwén granules + Ganciclovir + Moxifloxacin + Routine treatment | Ganciclovir + Moxifloxacin + Routine treatment | 10d |
| Yao et al. (2020) | Case-control study | Ordinary | Wuhan | Pulmonary tuberculosis, COPD, Hypertension, Diabetes, Chronic hepatitis B, Chronic liver disease | T:57.1 ± 14.0, C:62.4 ± 12.3 | T:21 (16/5), C:21 (12/9) | 42 | Liânhuá Qíngwén granules + Routine treatment | Routine treatment | NR |
| Xiao et al. (2020) | RCT | Mild | Wuhan | Pulmonary tuberculosis, COPD, Hypertension, Diabetes, Chronic hepatitis | T:43.26 ± 7.15 | T:32 (17/15), C:33 (19/14) | 65 | Toují Quén granules + Moxifloxacin + Ambroxol | Arbidol + Moxifloxacin + Ambroxol | 10d |
| Fu et al. (2020a) | RCT | Mild, Ordinary | Guangzhou | Hypertension, Coronary heart disease, Diabetes, Chronic hepatitis | T:45.26 ± 7.25 | T:37 (19/18), C:36 (19/17) | 73 | Toují Quén granules + Arbidol + Ambroxol | Arbidol + Ambroxol | 15d |
| Fu et al. (2020b) | RCT | Ordinary | Guangzhou | Pulmonary tuberculosis, Chronic hepatitis | T:51.99 ± 13.88 | T:82 (39/43), C:41 (23/18) | 123 | Jìnhuá Qínggàn granules + Routine treatment | Routine treatment | 5d |
| Yang et al. (2020a) | Case-control study | Ordinary | ShanXi, Hubei | Pulmonary tuberculosis, COPD, Hypertension, Diabetes, Chronic hepatitis | T:50.35 ± 13.37 | T:26 (16/10), C:23 (9/14) | 49 | Reyănning Mixture + Lopinavir + α-interferon + Arbidol hydrochloride + Ribavirin injection | Lopinavir + α-interferon + Arbidol hydrochloride + Ribavirin injection | 7d |
| Zhang et al. (2020a) | Case-control study | Ordinary | Wuhan | Pulmonary tuberculosis, COPD, Heart disease, Diabetes mellitus | T:53.7 ± 3.5, C:55.6 ± 4.2 | T:22 (9/13), C:23 (10/13) | 45 | Jìwèiyídáyán decoction + Routine treatment | Routine treatment | 7d |
| Huang et al. (2020) | Case-control study | Ordinal (56), Severe (12) | Hubei | Hypertension, Diabetes mellitus | T:60.42 ± 12.84, C:61.16 ± 13.58 | T:53 (25/28), C:15 (6/9) | 68 | Pneumonia No.1 Prescription and Pneumonia No.2 Prescription + Routine treatment | Routine treatment | 10d |
| Duan et al. (2020) | RCT | Mild | Hubei | COPD, Diabetes, Hypertension, Pulmonary tuberculosis, Chronic nephropathy, Chronic liver disease, Stroke | T:51.99 ± 13.88 | T:82 (39/43), C:41 (23/18) | 123 | Jìnhuá Qínggàn granules + Routine treatment | Routine treatment | 5d |
| Wang et al. (2020) | RCT | NR | Hubei | T1(Traditional Chinese medicine and fumigation); T2(Traditional Chinese medicine plus fumigation) | T1:10 (5/5), T2:10 (4/6) | T1:10 (5/5), T2:10 (4/6) | 30 | Traditional Chinese medicine and fumigation, Traditional Chinese medicine plus fumigation and absorption combined with super dose of vitamin E | Ribavirin + vitamin E + folic acid | NR |

(continued on next page)
| Study                     | Study design | Severity of disease | Original place of patients | Complications                                                                 | Age (Years) | Numbers of T/C (M/F) | Sample size | Intervention Treatment                                                                 | Control | Course of treatment |
|--------------------------|--------------|---------------------|-----------------------------|-------------------------------------------------------------------------------|-------------|----------------------|-------------|--------------------------------------------------------------------------------------|---------|---------------------|
| Yang et al. (2020b)      | Case-control study | Severe (65), Critical (3) | Wuhan | Hypertension, Diabetes, COPD, cerebrovascular disease, malignant tumor, Chronic nephropathy, Chronic liver disease | T:61.57 ± 1.84 C:66.46 ± 2.29 | T:51 (28/23) C:52 (24/28) | 103 | Chinese patent medicine or decoction + absorption combined with super dose of vitamin C: 54.90 ± 3.61 C: 55.90 ± 3.71 | Routine treatment | NR      |
| Li et al. (2020a)        | Case-control study | NR                  | Hubei | NR | T:53.600 ± 0.259 C:50.433 ± 0.338 | T:30 (15/15) C:30 (13/17) | 60 | Modified Qingfeipaidu decoction + Nutritional support + Respiratory support + Arbidol + Lopinavir + Xuebijing + Arbidol + Interferon + support therapy | Nutritional support + Respiratory support + Arbidol + Lopinavir + Interferon + support therapy | 3d      |
| Zhang et al. (2020b)     | Case-control study | Ordinary (44)       | Hubei | NR | T:49.05 ± 14.19 C:45.95 ± 14.68 | T:22 (10/12) C:22 (12/10) | 44 | Jinhua Qinggan granules + Oxygen inhalation + symptomatic and nutritional treatment | Oxygen inhalation + symptomatic and nutritional treatment | 7d      |
| Liu et al. (2020)        | Case-control study | NR                  | Beijing | Hypertension, Coronary heart disease, Diabetes, Cirrhosis (Average) | T:50.73 C:51.75 (Average) | T:44 (21/23) C:36 (16/20) | 80 | Interferon + Ribavirin + Carbostyril + Respiratory support | Interferon + Ribavirin + Carbostyril Respiratory support | 7d      |
| Ding et al. (2020)       | RCT           | Mild (21), Ordinary (70), Severe and Critical (9) | Wuhan | NR | T:54.7 ± 21.3 C:50.8 ± 23.5 | T:51 (39/12) C:49 (39/10) | 100 | Qingfei Touxie Fuzheng Recipe + Interferon + Ribavirin + Carbostyril + Respiratory support | 10d      |

* Toujie Quwen granules and Pneumonia No.1 Prescription shared the same herbal ingredients; NR: Not Report.
We included studies if they meet the following criteria: 1) the study population involved COVID-19 patients, and COVID-19 was defined based on the guidelines published by the NHC PRC (NHC, 2020a); 2) the intervention was CHM or CHM in combination with other treatments; 3) the control group was placebo or other therapy; and 4) study types were randomized controlled trials (RCT), cohort, and case-control studies.

We excluded the literature if: 1) manipulative treatments, such as acupuncture were performed; 2) the language was not English or Chinese; 3) full texts were not available; and 4) duplicated studies were published in English and Chinese.

Study selection
Two researchers (J.L and Y.Z) independently conducted the risk of bias assessment. Two-sided P values <0.05 were considered statistically significant. Statistical heterogeneity was assessed with the I² statistic, with values >50% indicating substantial heterogeneity. Subgroup analyses were performed, if heterogeneity was detected, based on the severity of the disease, study type, and complications, and we also considered sensitivity analyses where one study was excluded at a time. Egger test was used to assess publication bias. Qualitative descriptive analysis was used if the heterogeneity of the included studies was large or the data could not be pooled.

Results
Results of study selection
A total of 10,099 records were retrieved and, after elimination of duplicates, the titles and abstracts of 1,910 records were screened. After a final screening, we included 19 studies with 1474 patients (Cheng et al., 2020; Qu et al., 2020; Shi et al., 2020; Xia et al., 2020; Lv et al., 2020; Yao et al., 2020; Xiao et al., 2020; Fu et al., 2020a; Fu et al., 2020b; Yang et al., 2020a; Zhang et al., 2020b; Huang et al., 2020; Duan et al., 2020; Wang et al., 2020; Yang et al., 2020b; Li et al., 2020a; Zhang et al., 2020b; Liu et al., 2020; Ding et al., 2020). The screening process is detailed in Figure 1.

Characteristics of included studies
All 19 included studies were conducted in China. Six (31.6%) of these were RCTs (Xiao et al., 2020; Fu et al., 2020a; Fu et al., 2020b; Duan et al., 2020; Wang et al., 2020; Ding et al., 2020) and the rest were case-control studies (Cheng et al., 2020; Qu et al., 2020; Shi et al., 2020; Xia et al., 2020; Lv et al., 2020; Yao et al., 2020; Yao et al., 2020b; Yang et al., 2020a; Zhang et al., 2020a; Huang et al., 2020; Wang et al., 2020; Yang et al., 2020b; Li et al., 2020a; Zhang et al., 2020b; Liu et al., 2020). All research interventions were CHM in combination with other treatments. Basic characteristics are detailed in Table 1.

Risk of Bias
Two researchers (J.L and Y.Z) independently conducted the risk of bias evaluation of the included studies. Disagreements were resolved by consensus or by consulting a third researcher (X.L). For RCTs, we used the Cochrane Risk-of-Bias (RoB) assessment tool (Higgins et al., 2011) consisting of seven domains: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective outcome reporting, and other bias. For cohort and case-control studies, we used the Newcastle-Ottawa Scale (NOS) consisting of three domains (selection of exposure, comparability, and assessment of outcome) (Wells et al., 2003). The maximum score was nine, and studies with scores of seven or more were graded as high quality while those with scores less than seven were considered low quality.

Quality of evidence
We assessed the quality of evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach (Guyatt et al., 2008), and classified the studies as “high,” “moderate,” “low,” or “very low” quality. According to the GRADE approach, direct evidence from RCTs begins at high quality, and evidence from observational studies is considered low quality. The quality can be downgraded for five reasons (risk of bias, imprecision, inconsistency, indirectness, and publication bias) and upgraded for three reasons (large magnitude of an effect, dose-response gradient, and effect of plausible residual confounding).

Data synthesis and analyses
We conducted meta-analyses using the STATA version 14.0 software. For dichotomous data, we calculated the odds ratios (OR) with 95% confidence intervals (CI); for continuous data, we calculated weighted mean differences (WMD) with 95% CI. Missing data were dealt with according to the Cochrane Handbook for Systematic Reviews of Interventions. Two-sided P values <0.05 were considered statistically significant. Statistical heterogeneity was assessed with the I² statistic, with values >50% indicating substantial heterogeneity. Subgroup analyses were performed, if heterogeneity was detected, based on the severity of the disease, study type, and complications, and we also considered sensitivity analyses where one study was excluded at a time. Egger test was used to assess publication bias. Qualitative descriptive analysis was used if the heterogeneity of the included studies was large or the data could not be pooled.
Phytomedicine 85 (2021) 153282

Overall clinical effectiveness

The results of our meta-analysis for details). The quality of evidence was very low (Qu et al., 2020; Yang et al., 2020a; Huang et al., 2020; Zhang et al., 2020b; Liu et al., 2020).

Disappearance rate of symptoms (fever, cough, and fatigue)

A total of five studies reported the rates of disappearance of fever and cough (Cheng et al., 2020; Lv et al., 2020; Yao et al., 2020; Duan et al., 2020; Ding et al., 2020) and four studies reported the fatiguedisappearance rate (Cheng et al., 2020; Lv et al., 2020; Yao et al., 2020; Duan et al., 2020). Meta-analysis suggested that the rates of disappearance of fever (OR = 3.17, 95% CI 1.95-5.15, I² = 0%), cough (OR = 2.95, 95% CI 1.88-4.63, I² = 0%), and fatigue (OR = 2.61, 95% CI 1.56-4.34, I² = 0%) were higher in the CHM combination group compared to the control group (Figure 6). The quality of evidence was low.

Length of hospital stay

Five studies reviewed the length of hospital stay of patients with COVID-19. The results of the meta-analysis showed that there was no significant difference in the length of hospital stay of COVID-19 patients between the CHM combination and control groups (WMD = -0.46, 95% CI -3.87 - 2.95, I² = 99.5%), as shown in Figure 7. The quality of evidence was very low (Shi et al., 2020; Xia et al., 2020; Yang et al., 2020a; Li et al., 2020a; Zhang et al., 2020b).

Rate of adverse effects

A total of fifteen studies reported on the rate of adverse effects (AE) (Qu et al., 2020; Xiao et al., 2020; Huang et al., 2020; Duan et al., 2020; Yang et al., 2020b; Li et al., 2020a; Zhang et al., 2020b; Ding et al., 2020; Xiao et al., 2020; Lv et al., 2020; Fu et al., 2020a; Fu et al., 2020b; Yang et al., 2020a; Zhang et al., 2020a; Liu et al., 2020). However, eight of these studies reported no adverse events in either group (Qu et al., 2020; Xiao et al., 2020; Huang et al., 2020; Duan et al., 2020; Yang et al., 2020b; Li et al., 2020a; Zhang et al., 2020b; Ding et al., 2020). The main adverse reactions were gastrointestinal reactions such as nausea, abdominal pain, and diarrhea, which could be relieved with rest. Meta-analysis indicated no significant difference in AE between COVID-19 patients in the CHM combination and control groups (OR = 1.21, 95% CI 0.48-3.07, I² = 43.5%, Figure 8). The quality of evidence was low.

Subgroup and Sensitivity Analyses

We performed a subgroup analysis of the primary outcome based on study type, disease severity, and presence or absence of comorbidities. The results of the subgroup analyses revealed more effective outcomes in the CHM combination group than control group. Detailed results of the analyses are shown in Table 4. Furthermore, we performed sensitivity analyses with the use of a metaninf command in the STATA software for

### Table 2 Risk of bias of included RCTs.

| Study                | Random sequence generation | Allocation concealment | Blinding of participants | Blinding of personnel | Blinding of outcome assessment | Incomplete outcome data | Selective reporting | Other sources of bias |
|----------------------|----------------------------|------------------------|--------------------------|-----------------------|-------------------------------|------------------------|---------------------|----------------------|
| Xiao et al. (2020)   | Unclear                    | Unclear                | Unclear                  | Unclear               | Unclear                       | Low                    | Low                 | Low                  |
| Fu et al. (2020a)    | Low                        | Unclear                | Unclear                  | Unclear               | Unclear                       | Low                    | Low                 | Low                  |
| Fu et al. (2020b)    | Unclear                    | Unclear                | Unclear                  | Unclear               | Unclear                       | Low                    | Low                 | Low                  |
| Duan et al. (2020)   | High                       | Unclear                | Unclear                  | Unclear               | Unclear                       | Low                    | Low                 | Low                  |
| Wang et al. (2020)   | Unclear                    | Unclear                | Unclear                  | Unclear               | Unclear                       | Low                    | Low                 | Low                  |
| Ding et al. (2020)   | Low                        | Unclear                | Unclear                  | Unclear               | Unclear                       | Low                    | Low                 | Low                  |

### Risk of Bias

Of the six randomized controlled trials included, only two (Fu et al., 2020a; Ding et al., 2020) were considered low risk in the generation of randomized sequences, and both allocation concealment and blinding methods were unclear (Table 2).

All thirteen case-control studies had a risk of bias score of seven, none of which reported the comparability of cases and controls based on the design or analysis (See Table 3 for details).

### Primary outcome

#### Overall clinical effectiveness

Ten studies (Cheng et al., 2020; Shi et al., 2020; Xia et al., 2020; Xiao et al., 2020; Fu et al., 2020a; Fu et al., 2020b; Yang et al., 2020a; Li et al., 2020a; Zhang et al., 2020b; Liu et al., 2020) reported on the overall clinical effectiveness of CHM treatment. The results of our meta-analysis showed that the overall clinical effectiveness of COVID-19 treatment was better in the CHM combination group than in the control group, and the difference was statistically significant (OR = 2.67, 95% CI 1.83-3.89, I² = 0%), as shown in Figure 2. The quality of evidence was low.

### Secondary outcomes

#### Improvement in CT scan

Thirteen trials evaluated the improvements in CT scan findings in the CHM combination and control groups. The meta-analysis revealed a significantly increasing improvement in CT scan findings in the CHM combination group (OR = 2.43, 95% CI 1.80-3.29, I² = 0%, Figure 3). The quality of evidence was low (Cheng et al., 2020; Shi et al., 2020; Xia et al., 2020; Xiao et al., 2020; Fu et al., 2020a; Yang et al., 2020a; Zhang et al., 2020b; Huang et al., 2020; Wang et al., 2020; Yang et al., 2020b; Li et al., 2020a; Zhang et al., 2020b; Ding et al., 2020).

#### Percentage of cases turning to severe/critical

A total of 11 studies reported aggravation in COVID-19 after treatment. Percentage of cases turning to severe/critical was significantly lower in the CHM combination group than in the control group, (OR = 0.40, 95% CI 0.24-0.67, I² = 17.1%, Figure 4). The quality of evidence was low (Fu et al., 2020a; Huang et al., 2020; Li et al., 2020a; Xia et al., 2020; Lv et al., 2020; Yang et al., 2020b; Fu et al., 2020b; Cheng et al., 2020; Ding et al., 2020; Shi et al., 2020; Yang et al., 2020a).

#### RT-PCR negativity rate

Five studies reported on the RT-PCR negativity rate. The results of our meta-analysis suggested that RT-PCR negativity rate was higher in the CHM combination group than control group (OR = 2.55, 95% CI 1.06-6.17, I² = 56.4%). As shown in Figure 5. The quality of evidence was very low (Qu et al., 2020; Yang et al., 2020a; Huang et al., 2020; Zhang et al., 2020b; Liu et al., 2020).
| Study                | Is the case definition adequate | Representativeness of the cases | Selection of controls | Definition of controls | Comparability of cases and controls on the basis of the design or analysis | Ascertainment of exposure | Same method of ascertainment for cases and controls | Non-response rate | Total |
|---------------------|---------------------------------|---------------------------------|-----------------------|-----------------------|--------------------------------------------------------------------------|---------------------------|--------------------------------------------------|-------------------|-------|
| Cheng et al. (2020) | 1                               | 1                               | 1                     | 1                     | 0                                                                         | 1                         | 1                                                | 1                 | 7     |
| Qu et al. (2020)    | 1                               | 1                               | 1                     | 1                     | 0                                                                         | 1                         | 1                                                | 1                 | 7     |
| Shi et al. (2020)   | 1                               | 1                               | 1                     | 1                     | 0                                                                         | 1                         | 1                                                | 1                 | 7     |
| Xin et al. (2020)   | 1                               | 1                               | 1                     | 1                     | 0                                                                         | 1                         | 1                                                | 1                 | 7     |
| Lv et al. (2020)    | 1                               | 1                               | 1                     | 1                     | 0                                                                         | 1                         | 1                                                | 1                 | 7     |
| Yao et al. (2020)   | 1                               | 1                               | 1                     | 1                     | 0                                                                         | 1                         | 1                                                | 1                 | 7     |
| Yang et al. (2020a) | 1                               | 1                               | 1                     | 1                     | 0                                                                         | 1                         | 1                                                | 1                 | 7     |
| Zhang et al. (2020a)| 1                               | 1                               | 1                     | 1                     | 0                                                                         | 1                         | 1                                                | 1                 | 7     |
| Huang et al. (2020) | 1                               | 1                               | 1                     | 1                     | 0                                                                         | 1                         | 1                                                | 1                 | 7     |
| Yang et al. (2020b) | 1                               | 1                               | 1                     | 1                     | 0                                                                         | 1                         | 1                                                | 1                 | 7     |
| Li et al. (2020a)   | 1                               | 1                               | 1                     | 1                     | 0                                                                         | 1                         | 1                                                | 1                 | 7     |
| Zhang et al. (2020b)| 1                               | 1                               | 1                     | 1                     | 0                                                                         | 1                         | 1                                                | 1                 | 7     |
| Liu et al. (2020)   | 1                               | 1                               | 1                     | 1                     | 0                                                                         | 1                         | 1                                                | 1                 | 7     |
overall clinical effectiveness, and the results were not significantly different from those of the primary analysis, as shown in Figure 9.

**Publication Bias**

We used the `metabias6` command in the STATA software to test the publication bias. The result did not reveal any publication bias ($P > |t| = 0.072)$ (See Figure 10 for details).

**Discussion**

Our systematic review suggested that CHM combination therapy was more effective in the treatment of patients with COVID-19, in reducing the rate of aggravation of the condition and control of symptoms.
However, there was no difference in parameters of safety and reduction of mortality between the test and control groups in the included studies. The quality of evidence of the included studies was very low to low. CHM showed good clinical efficacy and immense potential in the treatment of COVID-19 (Zhang et al., 2020c). As a representative dosage form widely used in clinical practice, CHM decoction was found effective in the treatment of COVID-19, probably by alleviating the "cytokine storm". A review (Ren et al., 2020) suggested that its potential mechanism was inhibiting the arachidonic acid metabolism and regulating cytokine levels.

Various decoctions were used in the studies included in this systematic review. Through frequency analysis of all decoctions, we found that Ephedrae Herba (Chinese pinyin: mahuang), Armeniacae Semen Amurum (Chinese pinyin: kuxingren), Glycyrrhizae Radix et Rhizoma (Chinese pinyin: gancao), Pinelliae Rhizoma (Chinese pinyin: banxia), and Citri Reticulatae Pericarpium (Chinese pinyin: chenpin) were the most commonly used Chinese medicines. An in vitro study (Zhong et al., 2018) found that Amygdalin, an active ingredient extracted from Armeniacae Semen Amarum could inhibit the expression of interleukin (IL)-17A, IL-23, chemokine (C-C motif)
ligand (CCL) 2, and CCL5, and prevent the over activation of NF-κB and p38 MAPK signaling pathways, thereby inhibiting inflammation. An animal study (Lv et al., 2017) suggested that amygdalin inhibited the inflammatory response by reducing the expression of pro-inflammatory cytokines, including IL-1β, IL-6, and tumor necrosis factor (TNF)-α.

In addition to decoction, Chinese patent medicine, the modernized forms of traditional Chinese medicine, have also been widely used in the treatment of COVID-19. This study showed that the most commonly used Chinese patent medicines were Lianhua Qingwen granules and Xuebijing. One study showed that Lianhua Qingwen capsule could inhibit the cytokine storm induced by SARS-COV-2 by inhibiting the expression of TNF-α, IL-6, CCL-2/monocyte chemoattractant protein (MCP)-1, and C-X-C motif chemokine (CXCL)-10/interferon gamma-induced protein (IP)-10 (Li et al., 2020b). The capsule was also reported to have antiviral activity in vitro and could inhibit replication of SARS-COV-2 in cells. The results of a RCT showed that routine treatment combined with injection of Xuebijing could effectively improve pneumonia, mortality, and the duration of mechanical ventilation in patients.

**Figure 6.** Meta-analysis of disappearance rate of symptoms (fever, cough, and fatigue) in the CHM combination group vs. control group in COVID-19 patients.

| Study ID | OR (95% CI) | % Weight |
|---------|-------------|----------|
| Fever   | 3.11 (1.10, 8.75) | 22.03    |
| Lv R et al | 3.11 (1.10, 8.75) | 22.03    |
| Yao K et al | 4.50 (1.01, 20.11) | 10.52    |
| Duan C et al | 2.58 (1.20, 5.57) | 39.90    |
| Ding X et al | 6.98 (0.61, 60.25) | 5.07     |
| Subtotal | | 100.00   |

**Figure 7.** Meta-analysis of the length of hospital stay of COVID-19 patients.

| Study ID | OR (95% CI) | % Weight |
|---------|-------------|----------|
| Fever   | 3.11 (1.10, 8.75) | 22.03    |
| Lv R et al | 3.11 (1.10, 8.75) | 22.03    |
| Yao K et al | 4.50 (1.01, 20.11) | 10.52    |
| Duan C et al | 2.58 (1.20, 5.57) | 39.90    |
| Ding X et al | 6.98 (0.61, 60.25) | 5.07     |
| Subtotal | | 100.00   |

**NOTE:** Weights are from random effects analysis
with severe pneumonia (Song et al., 2019). An animal experiment found that Xuebijing could down-regulate the expression of inflammatory cytokines such as IL-6, TNF-α, MCP-1, macrophage chemotactic protein-2 (MIP-2), and IL-10 (Li et al., 2020c). Xuebijing demonstrated a good down-regulating effect on inflammatory reactions. The above studies showed that the Chinese patent medicines, Lianhua Qingwen and Xuebijing, played an important role in the treatment of COVID-19.

Our study showed that treatment with CHM combination could reduce the symptoms of fever, cough, and fatigue in patients with COVID-19, and did not exclude the placebo effect. However, our study also found that combined CHM treatment could improve CT findings as well as objective outcomes of RT-PCR negativity rate. We are therefore confident of the results of our study. Although our study showed no difference in the length of hospital stay and AE in COVID-19 patients between the CHM combination and control groups, the findings indirectly suggested that the added effect of CHM was the improvement of symptoms of COVID-19.

Subgroup analyses found that both RCTs and case-control studies showed better results in the combined CHM group than the control group. Comorbidities did not influence the effectiveness of combined CHM treatment of patients with COVID-19. At the same time, the combination therapy did not seem to have different effects depending on the severity of COVID-19. However, given the delayed efficacy of CHM, it may not be possible to treat patients with severe disease. This could be considered a limitation of Chinese medicine in the treatment of COVID-19.

The findings of our study are consistent with previously published systematic reviews and meta-analyses. Wu et al. found that integrated treatment with traditional Chinese and western medicines could reduce the conversion rate of severe cases, improve the clinical cure rate, along with certain advantages in relieving cough and fever in patients with COVID-19 (Wu et al., 2020). However, only eight studies were included

| Subgroup analysis of the overall clinical effectiveness. |
|--------------------------------------------------------|
| Subgroup | Studies | Statistical method | Effect estimate | I-squared |
| RCT       | 3 (Xiao et al., 2020; Fu et al., 2020a; Fu et al., 2020b) | OR, Random | 3.06, 95%CI [1.68-5.59] | 0% |
| CSS       | 7 (Cheng et al., 2020; Shi et al., 2020; Xia et al., 2020; Yang et al., 2020a; Li et al., 2020a; Zhang et al., 2020b; Liu et al., 2020) | OR, Random | 2.44, 95%CI [1.51-3.96] | 0% |
| Disease severity | Mild case | 6 (Cheng et al., 2020; Xiao et al., 2020; Fu et al., 2020a; Fu et al., 2020b; Yang et al., 2020a; Zhang et al., 2020b) | OR, Random | 2.52, 95%CI [1.66-3.83] | 0% |
| | Mixed case | 4 (Shi et al., 2020; Xia et al., 2020; Li et al., 2020a; Liu et al., 2020) | OR, Random | 3.40, 95%CI [1.44-8.05] | 0% |
| With or without comorbidities | With | 6 (Cheng et al., 2020; Shi et al., 2020; Xia et al., 2020; Fu et al., 2020a; Fu et al., 2020b; Liu et al., 2020) | OR, Random | 3.88, 95%CI [2.17-6.95] | 0% |
| | Without | 4 (Xiao et al., 2020; Yang et al., 2020a; Li et al., 2020a; Zhang et al., 2020b) | OR, Random | 2.04, 95%CI [1.25-3.34] | 0% |
in the aforementioned review, including one RCT, one before and after trial, two case series studies, and four retrospective studies. Luo et al. suggested that a Chinese herbal formula could be an alternative approach for prevention of COVID-19 in high-risk populations (Luo et al., 2020); however, the conclusions of the study were based on indirect evidence (from SARS and H1N1). Li et al. conducted a systematic review and meta-analysis on CHM for COVID-19 (Li et al., 2020d); however, included only RCTs and quasi-RCTs. Moreover, the primary and secondary outcomes were not similar to our study.

We examined the quality of evidence of the included studies using GRADE approach. Meanwhile, we conducted a systematic and comprehensive literature search and supplemented with the grey literature. However, this study may have the following limitations. First, the low quality of the studies included in this review, especially RCTs, may have affected our results; however, due to the gravity of the COVID-19 outbreak, low-quality clinical trials should be considered. Second, since the authors of the study speak only Chinese and English, literature in other languages were not included, causing a potential language bias. Third, due to the heterogeneity of standard-of-care for COVID-19 in each study was large, potential bias may arise. Lastly, as the COVID-19 epidemic has not yet fully subsided and more large-sample clinical studies are ongoing, evidence from the current analysis is incomplete, and further updates are expected to complement the results of this systematic review after full control of the epidemic (Norris, 2018).

In conclusion, the combined treatment of COVID-19 with Chinese and Western medicines may be effective in controlling symptoms and reducing the rate of disease progression. However, the safety of this combined approach remains unknown and large sample, high quality multicenter randomized controlled trials must be conducted in the future.

Figure 9. Sensitivity analyses of overall clinical effectiveness in COVID-19 patients.

Figure 10. Publication bias test.
Authors’ contributions
L.X.F. conducted data-analysis and drafted the manuscript; N.X.J. designed the study, interpreted the results, and drafted the manuscript; L.J.H. and Z.Y.D. searched the literature, collected the data and assessed the methodological quality of included studies; W.L., H.D.H., L.Y.T., G.J. W. and W.W.X. assisted with the design of PICOs and interpreted the results. C.Y.F. conceived the study and oversaw the study implementation; C.Y.L. provided the methodological guidance; L.L. conceived the study, designed the PICOs and interpreted the study results; All authors read and approved the final manuscript.

Funding
Guangdong Provincial Key Laboratory of Research on Emergency in TCM (No. 2017B030314176).

Declaration of Competing Interest
The authors declare that they have no competing interests.

Acknowledgement
We thank Mengjiao Ren and Ling Wang, from School of Public Health of Lanzhou University for conducting data extraction. We thank all the authors for their wonderful collaboration.

Supplementary materials
Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.phymed.2020.153282.

References
Ang, L., Lee, H.W., Choi, J.Y., Zhang, J., Lee, L.M., 2020. Herbal medicine and pattern identification for treating COVID-19: a rapid review of guidelines. Integr Med Res 9, 100407.
Cheng, D.Z., Li, Y., Li, W.D., Zhou, B., Song, Q.Y., 2020. Efficacy analysis on 51 cases of COVID-19 treated with Traditional Chinese Medicine Lianhua Qingwen: a multi-center retrospective study. Tianjin J Tradit Chin Med 1–6.
Ding, X.J., Zhang, Y., He, H.C., Zhang, M.Y., Li, Y., C., Wu, W., Yang, W.C., Huang, H.S., Liu, L., 2020. Clinical Effect and Methodology of Qingfei Touxi Fuzheng Recipe in the Treatment of Novel Coronavirus Pneumonia. Her Med 1–10.
Du, H.Z., Hou, X.Y., Huang, B.S., Liu, D.H., 2020. Traditional Chinese Medicine: an effective treatment for 2019 novel coronavirus pneumonia (COVID-19) in China: a systematic review and meta-analysis. Syst Rev 9, 75.
Luo, H., Zhang, Q.L., Li, X.H., Li, Y., Wang, X., Guo, L., Ma, Q., Zhao, J., Jia, Z.H., Shi, Y.X., Li, C.F., 2020. XueBiJing Injection Versus Placebo for Critically Ill Patients With Acute Respiratory Failure Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection. Crit Care Med 48, 467–474.
Liu, Z.L., Li, Y., Hou, C.Y., Li, L., Luo, X.L., Zhang, C., Yang, J.J., Li, J.Y., An, A.H., Li, H.Y., Zeng, Y., Li, T., Wang, X.Z., 2020. Clinical Observation and evaluation of Jinhu갯 Qinqang Granules in the Treatment of Novel Coronavirus Pneumonia. J Tradit Chin Med 1–6.
Luo, H., Tang, Q.L., Shang, X.Y., Li, A., Morgan, Y., Robinson, N., Liu, J.P., 2020. Can Traditional Chinese Medicine Be Used for Prevention of Coronavirus Disease 2019 (COVID-19)? A Review of Historical Classics, Research Evidence and Current Prevention Programs. Chin J Integ Med 26, 243–250.
Luo, X.P., Ni, X.J., Lin, J.H., Zhang, Y.D., 2020a. The add-on effect of Chinese herbal medicine on COVID-19: a systematic review and meta-analysis. INPLASY202004190. https://inplasy.com/inplasy-2020-4-0190/.
Lv, J., Xiong, W., Lei, T., H., Sun, M., Tan, W., Wang, Z., Huang, X., Deng, S., Dang, J., Wang, Y., 2017. Myalgidilamine ameliorates the progression of alveolar hypoplasia in LDReceptor deficient. Mol Med Rep 16, 8171–8179.
Lv, R.B., Wang, W.J., Li, X., 2020. Clinical observation on 63 suspected cases of COVID-19 treated with Traditional Chinese Medicine Lianhua Qingwen. J Tradit Chin Med 1–5.
Mohr, D., Liberatori, A., Tetzlaff, J., Altmann, D.G., PRISMA Group, 2009. PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-analyses: the PRISMA statement. BMJ 339, b2535.
NHC. 2020a. Notice on the issue of the new 7th version of the COVID-19 Diagnosis and Treatment Guideline. NHC. http://www.nhc.gov.cn/yzygj/s7653p/202003/4e6c29a47d34efc80beb75f912e1b9f8/files/ce3e6945832a3e83ae4e15550bce964.pdf.
NHC. 2020b. Notice on the issue of the new 3rd version of the COVID-19 Diagnosis and Treatment Guideline. NHC. http://www.nhc.gov.cn/yzygj/s7653p/202001/f492c593e5e9d7be587e2c2f6a1f3a3e3f78d964be811177367d87981983d87f88b3.tf.pdf.
Norris, S.L., 2018. Meeting public health needs in emergencies – World Health Organization guidelines. J. Evid. Based. Med. 11, 133–135.
Qu, X.K., Hao, S.L., Ma, J.H., Wei, G.Y., Song, K.Y., Tang, C., Gao, Y.F., Liang, S.Q., Du, W.J., 2020. Observation on the clinical effects of Shufeng Jiedu Capsule combined with Arbidol Hydrochloride Capsules in the treatment of COVID-19. Zhong Cao Yao 51, 1167–1170.
Ren, Y., Yao, M.C., Hao, X.Q., Guo, Y., Zhu, W.X., Qiao, Y.J., Zhang, Y.L., 2020. Study on treatment of “cytokine storm” by anti-2019-nCoV prescriptions based on arachidonic acid metabolic pathway. Zhongguo Zhong Ya Zhi 45, 1225, 123.
She, J., Jiang, J., Ye, L., Hu, L., Bai, C., Song, Y., 2020. 2019 novel coronavirus of pneumonia in Wuhan, China: emerging attack and management strategies. Clin Transl Med 9, 19.
Shi, J., Yang, Z.G., Ye, C., Chen, S.S., Lu, Y.F., Lv, X., Qu, X.N., Tang, B.Z., Yin, K.S., Chen, X.R., 2020. Clinical observation on 49 cases of non-critical coronavirus disease 2019 in Shanghai treated with traditional Chinese and western medicine. Shanghai J Tradit Chin Med 54, 30–35.
Song, Y., Yao, S., Yao, Y., Huo, H., Zhao, X., Xu, Y., K., Liu, L., Xu, Y., Liu, Z., Zhou, Q., Wang, Y., Ma, Z., Zheng, Y., Wu, D., Tang, Z., Zhang, M., Pan, S., Chai, Y., Song, Y., Zang, J., Pan, L., Liu, Y., Yu, H., Yu, Z., Zhang, H., Wang, X., Du, Z., Wans, X., Wang, Y., Tian, Y., Zhu, W., Wang, X., Yan, X., Liu, Z., Zhang, B., Zhong, N., Shang, H., Bai, C., 2019. XueBiJing Injection Versus Placebo for Critically Ill Patients With Severe Community-Acquired Pneumonia: A Randomized Controlled Trial. Crit Care Med 47, e72S–e742.
Wang, Y.L., Yang, X.D., Liu, Y.P., Zhang, J., Feng, Y.F., Shang, L., Zhang, K.W., Cheng, Z., 2020. Observation on clinical effect of modified Qingfeipaidu decoction in treatment of COVID-19. Zhong Cao Yao 51, 2046–2049.
Li, R.F., Hou, Y.L., Huang, J.C., Pan, W.Q., Ma, Q.H., Shi, Y.X., Li, C.F., Zhao, J., Jia, Z.H., Jiang, H.M., Zheng, K., Huang, S.X., Dai, J., Li, X.B., Hou, X.T., Wang, L., Zhong, N., Yang, Z.F., 2020b. Lianhuaqingwen exerts anti-viral and anti-inflammatory effects against novel coronavirus COVID-19. Pharmacol Res.
Ye, L., Li, X., Wang, J., Li, Y., Yu, F., Ma, J., Liu, Z., Zeng, P., Shi, T., Zeng, X., Pan, L., Qian, F., Yang, A., An, H., Zhang, Y., L., Zeng, Y., Li, G., Sun, Q., Sun, G.B., Li, Z.L., Li, Q.L., Li, P., Zhang, H.L., Wang, Y.W., Zhang, B.L., Liu, Q.O., 2020. Clinical observation of Jinhu갯 Qinqang Granules in the Treatment of Novel Coronavirus Pneumonia. J Tradit Chin Med 1–5.
Connell, D., Peterson, J., Welch, V., Losos, M., Tugwell, P., 2003. 'A Cochrane Collaboration filter for identifying randomized trials in meta-analyses. World Health Organization guidelines. J. Evid. Based. Med. 11, 133–135.
WHO, 2020a. Naming the coronavirus disease (COVID-19) and the virus that causes it. WHO. http://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-19)-and-the-virus-that-causes-it.
WHO, 2020b. Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV). WHO. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/techical-guidance/naming-the-coronavirus-disease-(covid-19)-and-the-virus-that-causes-it.
WHO, 2020c. Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV). WHO. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-19)-and-the-virus-that-causes-it.
WHO, 2020c. WHO Director-General’s opening remarks at the media briefing on COVID-19. WHO. https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19-11-march-2020.

WHO, 2020d. Coronavirus disease (COVID-19) situation reports-86. WHO. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200415-sitrep-86-covid-19.pdf?sfvrsn=c615ea20_6.

Wu, Y.Q., Zou, L., Yu, X., Sun, D., Li, S.R., Tang, L., Yang, J.R., Chen, X.Y., Wu, Y.G., Fang, H., 2020. Clinical effects of integrated traditional Chinese and western medicine on COVID-19: a systematic review. Shanghai J Tradit Chin Med 1–8.

Xia, W.G., An, C.Q., Zhen, C.J., Zhang, J.X., Huang, M., Wang, Y., Yang, F.W., Duan, C., Li, Z.L., Liu, Q.Q., Zhang, B.L., 2020. Clinical study on 34 case of COVID-19 treated with integrated traditional Chinese and Western Medicine. J Tradit Chin Med 61, 375–382.

Xiao, Q., Jiang, Y.J., Wu, S.S., Wang, Y., An, J., Xu, W.P., Wu, J.J., 2020. Value analysis of Shufeng Jiedu Capsule combined with Arbidol Hydrochloride Capsules in the treatment of mild cases of COVID-19. J Emerg Tradit Chin Med 1–3.

Yang, M.B., Dang, S.S., Huang, S., Li, Y.J., Guo, Y.L., 2020a. Multi-center Clinical Observation of Reyanning Mixture in Treatment of Novel Coronavirus Pneumonia. Chin J Exp Tradit Med Form 1–6.

Yang, Q., Sun, Q.G., Jiang, B., Xu, H.J., Luo, M., Xie, P., Huang, W., Cong, Z.W., 2020b. Retrospective clinical study on treatment of COVID-19 patients with integrated traditional Chinese and Western medicine. Zhong Cao Yao 51, 2050–2054.

Yang, Y., Islam, M.S., Wang, J., Li, Y., Chen, X., 2020. Traditional Chinese Medicine in the Treatment of Patients Infected with 2019-New Coronavirus (SARS-CoV-2): A Review and Perspective. Int J Biol Sci 16, 1708–1717.

Yao, K.T., Liu, M.Y., Li, X., Huang, J.H., Cai, H.B., 2020. Retrospective Clinical Analysis on Treatment of Novel Coronavirus-infected Pneumonia with Traditional Chinese Medicine Lianhu Qingwen. Chin J Exp Tradit Med Form 1–7.

Zhang, C.T., Yang, Y., You, F.M., Huang, Q.S., Gao, P.Y., Tang, J.Y., Xie, C.G., Xiao, W., Sun, Z.T., Zhang, H., Qian, B., 2020b. Clinical Study on COVID-19 from the Perspective of “Yidujiashi” Theory. Pharm Clin Chin Materia Medica 1–8.

Zhong, X.Q., Zhong, Y., Wang, W., Zhang, X.Q., 2020b. Clinical observation of Xuebijing in the treatment of COVID-19. Chin Hosp Pharm J 1–5.

Zhong, Y.S., Cong, W.H., Zhang, J.J., Guo, F.F., Li, H.M., 2020c. Research progress of intervention of Chinese herbal medicine and its active components on human coronavirus. Zhongguo Zhong Yao Za Zhi 45, 1263–1271.

Zhong, X.Q., Li, L., Lu, C.J., Lu, Y., Wei, J.A., Han, L., 2018. Anti-inflammation Effect of Amygdalin on Macrophage 264.7 Cells Stimulated by Lipopolysaccharide. Tradit Chin Drug Res Clin Pharm 29, 257–263.